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Abstract
Introduction: Anemia is a frequently encountered problem during inflammation. Hepcidin is an interleukin-6 (IL-6)-
induced key modulator of inflammation-associated anemia. Human sepsis is a prototypical inflammatory syndrome,
often complicated by the development of anemia. However, the association between inflammation, hepcidin
release and anemia has not been demonstrated in this group of patients. Therefore, we explored the association
between hepcidin and sepsis-associated anemia.
Methods: 92 consecutive patients were enrolled after presentation on the emergency ward of a university hospital
with sepsis, indicated by the presence of a proven or suspected infection and ≥ 2 extended systemic inflammatory
response syndrome (SIRS) criteria. Blood was drawn at day 1, 2 and 3 after admission for the measurement of IL-6
and hepcidin-25. IL-6 levels were correlated with hepcidin concentrations. Hemoglobin levels and data of blood
transfusions during 14 days after hospitalisation were retrieved and the rate of hemoglobin decrease was
correlated to hepcidin levels.
Results: 53 men and 39 women with a mean age of 53.3 ± 1.8 yrs were included. Hepcidin levels were highest at
admission (median[IQR]): 17.9[10.1 to 28.4]nmol/l and decreased to normal levels in most patients within 3 days (9.5[3.4
to 17.9]nmol/l). Hepcidin levels increased with the number of extended SIRS criteria (P = 0.0005). Highest IL-6 levels
were measured at admission (125.0[46.3 to 330.0]pg/ml) and log-transformed IL-6 levels significantly correlated with
hepcidin levels at admission (r = 0.28, P = 0.015), day 2 (r = 0.51, P < 0.0001) and day 3 (r = 0.46, P < 0.0001). Twelve
patients received one or more blood transfusions during the first 2 weeks of admission, not related to active bleeding.
These patients had borderline significant higher hepcidin level at admission compared to non-transfused patients (26.9
[17.2 to 53.9] vs 17.9[9.9 to 28.8]nmol/l, P = 0.052). IL-6 concentrations did not differ between both groups. Correlation
analyses showed significant associations between hepcidin levels on day 2 and 3 and the rate of decrease in
hemoglobin (Spearman’s r ranging from -0.32, P = 0.03 to -0.37, P = 0.016, respectively).
Conclusions: These data suggest that hepcidin-25 may be an important modulator of anemia in septic patients
with systemic inflammation.
Introduction
Inflammation-associated anemia represents an important
and highly prevalent clinical problem. In 2000, Krause et al.
described a peptide that was later called ‘hepcidin’ based
on its hepatic expression and antimicrobial activity [1,2].
This b-defensin-like peptide was found to be a principle
regulator of systemic iron homeostasis. In concordance
with this dual function, its expression is modulated by sys-
temic iron requirements and inflammatory stimuli, as it is
induced by cytokines such as IL-6 [3]. Its role in the devel-
opment of anemia was first suggested in 2001 [4]. Since
then it has been demonstrated that hepcidin is a central
modulator of inflammation-associated anemia, not only by
controlling the expression of ferroportin on intestinal cells
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and macrophages [5], but also via a direct inhibitory effect
of hepcidin on erythropoiesis [6]. In humans, increased
concentrations of hepcidin were detected in patients with
chronic infections and severe inflammatory diseases [7].
The association of increased concentrations of hepcidin
with anemia has been determined in patients suffering
from chronic inflammation [8], chronic kidney disease [9],
and cancer [10]. In addition, acute systemic inflammation
evoked by experimental endotoxemia in humans resulted
in an increase in hepcidin release, associated with a
decrease in serum iron [11]. Nevertheless, the association
between the innate immune response, hepcidin release
and consequent decrease in hemoglobin (Hb) has not
been established in patients with an acute systemic
inflammation.
Human sepsis is a prototypical acute inflammatory
syndrome frequently complicated by the development of
anemia. As the incidence of sepsis is high [12], determi-
nation of this putative pathway of the development of
anemia is of clinical importance. Therefore, we explored
the correlation between IL-6 and hepcidin, and the sub-
sequent rate of Hb decrease and number of blood trans-
fusions received in septic patients.
Materials and methods
Subjects and sampling
This is an explorative observational study in which data
of the subjects were retrieved from a prospectively
aggregated database of patients with sepsis. Following
Dutch law, the local Institutional Review Board of Arn-
hem-Nijmegen indicated that no formal approval was
required for this study. Patients were informed, but no
written consent was necessary. Ninety-two consecutive
septic patients were enrolled after presentation on the
emergency ward and subsequent hospital admission.
Sepsis was defined by the presence of two or more
extended criteria for systemic inflammation (body tem-
perature >38.3 or < 36°C, acutely altered mental status,
shivering, heart rate >90 bpm, systolic blood pressure
<90 mmHg or mean arterial pressure < 65 mmHg,
respiratory rate >20 breaths/min, hyperglycemia in
absence of diabetes) and a proven or suspected source
of infection [13]. The total number of extended systemic
inflammatory response syndrome (SIRS) scores were cal-
culated. Patients were given usual care according to the
guidelines of the Surviving Sepsis Campaign [14]. Blood
was drawn at day one, two and three of admission for
the measurement of IL-6 and hepcidin-25. Hb measure-
ments were not taken as part of a protocol, but Hb
levels that were determined as part of standard hospital
care during the first 14 days after hospital admission
were retrieved and used for further analysis, Hemoblo-
bin levels were checked regularly, but not every day in
every patient. Also the accompanying indices of mean
corpuscular volume (MCV), mean cell Hb (MCH), and
red cell distribution width (RDW) were analyzed. Blood
transfusions during hospital stay were recorded. We
hypothesized that the effect of sustained elevated levels
of hepcidin could be first seen in the Hb level after a per-
iod of 7 to 14 days. This was based on the assumption
that erythrocytes circulate for approximately 120 days. If
erythropoiesis would be abrogated by hypoferremia due
to an increased hepcidin level, it would therefore take
approximately 12 days to reduce the Hb levels by 10%.
A decrease of 10% was considered a clinically relevant and
reliably detectable difference. However, due to a possible
direct inhibitory effect of hepcidin on erythropoiesis, and a
reduced erythrocyte half-life during inflammation, a
detectable reduction of Hb from day seven onwards was
anticipated.
Laboratory measurements
IL-6 levels were measured on an Immulite 2500 (Siemens,
Breda, The Netherlands), based on a solid-phase, enzyme-
labelled, chemiluminescent sequential immunometric
method. Serum hepcidin-25 measurements were
performed by a combination of weak cation exchange
chromatography and time-of-flight mass spectrometry
(TOF-MS), using a Microflex LT matrix-enhanced
laser desorption/ionisation TOF-MS platform (Bruker
Daltonics, Bremen, Germany). An internal standard (syn-
thetic hepcidin-24; Peptide International Inc., Louisville,
KT, USA) was used for quantification [15,16].
Calculations and statistical analysis
Log-transformed IL-6 concentrations were correlated
with hepcidin-25 concentrations using Pearson’s correla-
tion coefficient. Hepcidin-25 was correlated with the
rate of decrease of Hb between day 1 and 14, using
Spearman’s correlation coefficient. The rate of decrease
of Hb was calculated per patient by linear regression
using all available Hb measurements. If Hb levels were
not measured at days 7 to 14, or if patients received a
blood transfusion during their stay, they were excluded
from this analysis. Hepcidin levels at admission (prior to
any transfusion) of patients who received a blood trans-
fusion during the first 14 days of hospitalization were
compared with patients who did not.
To test whether the presence of comorbidity affected
the rate of Hb decrease, we divided different forms of
comorbidity into eight categories (chronic kidney dis-
ease, hematologic, malignancy, pulmonary, rheumatic/
autoimmune, cardiologic, urologic, and other) and per-
formed a step-wise multi-variate analysis in which hep-
cidin levels and the eight categories of comorbidity were
added to the model. If a comorbidity was found to sig-
nificantly attribute to the prediction of Hb decrease, it
was left in the model, but otherwise discarded. Data are
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expressed as mean ± standard error of the mean or
median (25th to 75th percentile) depending on their dis-
tribution. Correlations were expressed as Spearman’s
correlation coefficient, except for the correlations
between hepcidin and log-transformed IL-6 concentra-
tions that were expressed as Pearson’s r.
Paired observations over time were tested with
Wilcoxon matched-pairs test and unpaired observations
with a Mann-Whitney test.
Results
Demographic data
Demographic data of the subjects are displayed in Table
1. Two patients died during hospitalization. Blood cul-
ture results are presented in Table 2. Twenty percent of
the patients had a positive blood culture. This relatively
low percentage is probably due to the fact that in most
cases the general practitioner had already initiated anti-
microbial therapy before admission to the hospital.
IL-6 and hepcidin
IL-6 was highest at admission (125.0 (46.3 to 330.0) pg/ml),
and decreased on day two (37.2 (16.8 to 112.8) pg/ml) and
day three (19.5 (7.4 to 55.7) pg/ml). A similar pattern was
observed for hepcidin levels, being highest at admission
(17.9 (10.1 to 28.4) nmol/l) and declining to 9.5 (3.4 to
17.9) nmol/l on day three, which is still increased
compared with control values. Log-transformed IL-6 levels
correlated significantly with hepcidin levels on admission,
day two and day three, (Pearson’s r = 0.28, P = 0.015;
r = 0.512, P< 0.0001; r = 0.458, P< 0.0001, respectively;
Figure 1a). Also, the number of extended SIRS criteria pre-
sent correlated with hepcidin levels (Figure 1b).
Hepcidin and hemoglobin
Hb was 12.0 (11.2 to 13.4) g/dl at admission and decreased
to an average of 11.3 (10.3 to 12.8) g/dl at day 7 to 14 (P =
0.004) in patients who did not receive a blood transfusion.
During hospitalization the Hb levels decreased at least 0.8
g/dl in 69 (86%) of 80 patients who did not receive a blood
transfusion. There was no correlation between hepcidin
levels and Hb levels at admission (r = 0.21, P = 0.07).
Hepcidin levels on day one of admission did not correlate
Table 1 Demographic data of the subjects
Number (%)
Total 92 (100)
Male/female 53/39 (58/42)
Age (years) 53.3 ± 1.8
ICU admissions 3 (3)
Deaths 2 (2)
Median hospital length of stay (days) 6 (4-11)
Number of SIRS criteria present 2.5 ± 0.9
Number of patients transfused 12 (13)
Site of infection
Lung 28 (30)
Abdomen 12 (13)
Urinary tract 24 (26)
Skin/soft tissue 4 (4)
Bone/joint 3 (3)
Blood 2 (2)
Cerebral 1 (1)
Other 3 (3)
Unknown 9 (10)
No infectious focus 6 (7)
Comorbidity
None 36 (39)
Chronic kidney disease 13 (14)
Hematologic disease 7 (8)
Malignancy 8 (9)
Lung disease 6 (7)
Rheumatic / autoimmune disease 2 (2)
Cardial disease 1 (1)
Urological disease 5 (5)
Other 14 (15)
Data are expressed as absolute numbers and percentages of total, mean ±
standard error of the mean or median (25th to 75th percentile). Multivariate
analysis demonstrated that comorbidities were not independently associated
with hemoglobin decrease. SIRS, systemic inflammatory response syndrome.
Table 2 Blood culture results
Organisms and culture sites Number of patients
Organisms
Aeromonas species 1
Candida species 2
Citrobacter species 1
Corynebacterium jeikeium 1
Coxiella species 4
Enterobacter species 1
Enterococcus species 5
Escherichia coli 10
Haemophilus influenzae 1
Klebsiella species 2
Morganella species 1
Pseudomonas species 3
Salmonella species 1
Staphylococcus species 2
Streptococcus species 3
Viral infection (positive serological test) 6
No pathogen cultured 50
Sites
Blood 18
Urine 18
Other 4
Multiple organisms 2
Multiple sites 2
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with the rate of decrease in Hb (r = -0.13, P = 0.39). Hep-
cidin on day two and day three significantly correlated
with the rate of decrease of Hb (r = -0.32, P = 0.03 and r =
-0.37, P = 0.016; Figure 1c).
Twelve patients received one or more blood transfusions
during the first two weeks of admission, not related to active
bleeding. These patients had borderline significant higher
hepcidin level at admission (preceding any blood transfu-
sion) compared with non-transfused patients (26.9 (17.2 to
53.9) vs 17.9 (9.9 to 28.8)nmol/l, P = 0.052; Figure 1d).
MCV slightly increased during hospital admission from
86.0 (84.0 to 90.0) to an average of 88.5 (85.7 to 92.6) fl at
day 7 to 14 (P = 0.011). RDW increased from 13.9 (13.1 to
15.4) to an average of 15.9 (14.2 to 17.0)% (P = 0.002).
MCH remained unchanged during 14 days of follow up
(from 1.84 (1.75 to 1.90) fmol to an average of 1.82 (1.76
to 1.90) fmol at day 7 to 14 (P = 0.39)). None of the
changes in red cell indices correlated with the hepcidin
levels on days one to three.
Discussion
In the present study, three novel findings emerged. This
is the first study to show that: hepcidin-25 is increased
during human sepsis; in septic patients the degree of
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Figure 1 Association between IL-6, hepcidin and hemoglobin decrease. (a) Humoral relation between inflammation and hepcidin levels:
Pearson’s correlation between the natural logarithm (Ln) of IL-6 and hepcidin-25 on day 2 (black diamonds, uninterrupted line), and day 3 (grey dots,
dashed line. The correlation on day 1 (r = 0.28, P = 0.015), was omitted for reasons of clarity. The median reference level of serum hepcidin-25 is 4.2
nM, range 0.5 to 13.9 nM [15]. (b) Clinical relation between inflammation and hepcidin levels: hepcidin-25 levels according to the number of extended
systemic inflammatory response syndrome (SIRS) criteria at presentation at the emergency ward [13]. Differences were tested with Kruskal-Wallis.
(c) Spearman’s correlation between rate of hemoglobin (Hb) decrease and hepcidin-25 concentration on day 2 (black dots, uninterrupted line) and
day 3 (open triangles, dashed line). The rate of decrease was only calculated in patients that did not receive a blood transfusion and of whom Hb was
measured at least once between day 7 and 14 of hospital admission (n = 44). (d) Relation between hepcidin-25 levels at admission and the number of
blood transfusions received during 14 days of follow up. Boxes represent median and interquartile range, whiskers represent 5th and 95th percentile.
Difference between transfused and non-transfused patients was tested with a Mann Whitney test.
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inflammation, indicated by IL-6 levels and number of
SIRS criteria present, is associated with the elevated
concentrations of hepcidin; and persistently increased
levels of hepcidin-25 at day two and day three after
admission are associated with a decrease in Hb during
hospitalization. Naturally, in patients who received a
transfusion, the effect of hepcidin on Hb could not be
determined and these patients were excluded from this
part of the analysis. In a separate analysis, we showed
that transfused patients showed a trend towards higher
hepcidin levels than those who were not. These findings
combined suggest that the observed association between
elevated hepcidin and a decrease in Hb is likely to be an
underestimation.
This study does not necessarily indicate a causal rela-
tion between elevated hepcidin and Hb decrease in sep-
tic patients. However, the causal relation of the
induction of hepcidin by IL-6 and the development of
anemia by sustaining elevated hepcidin levels has been
shown by others in separate experiments [3,5,6,17]. This
study is the first to address the combined measurement
of hepcidin, IL-6 and Hb levels in patients and shows
that hepcidin probably plays a role in sepsis-associated
anemia. One may argue that the correlation between
inflammation, hepcidin and anemia is an epiphenome-
non, because more severely affected patients release
higher levels of inflammatory parameters and also
receive more fluids during their volume resuscitation,
resulting in the more pronounced decrease in Hb. This
appears not to be the case, because hepcidin concentra-
tions at admission did not predict the decrease in Hb, in
contrast to more prolonged elevations in hepcidin dur-
ing the first three days. Moreover, the decrease in Hb
was determined over 14 days, a period in which the
effects of volume resuscitation should have diminished.
Nevertheless, it is important that in addition to the phy-
siological role of hepcidin, several other factors that lead
to anemia during infection have been described, such as
iatrogenic blood loss, inhibition of erythropoietin pro-
duction [18], blunted erythropoietic response [18,19],
and a decreased lifespan of erythrocytes, mediated by
increased adherence to the vascular wall and phagocyto-
sis by macrophages [20]. In addition, in these patients
the presence of different comorbidities and the severity
of the disease could have influenced the development of
anemia. However, we were not able to express these
variables in size and number, and therefore could not
include these parameters as a continuous variable into a
multivariate regression analysis. This may explain the
relatively low correlation coefficients we found between
hepcidin and Hb decrease.
There are two known ways that hepcidin can result in
inflammation-associated anemia. First, hepcidin can
abrograte erythroid colony formation in situations
where erythropoietin concentrations are reduced, as is
the case during sepsis [6]. Furthermore, inflammation
leads to sequestration of iron in cells resulting in a
blocked transport of iron to the bone marrow. Consider-
ing the fact that the lifespan of erythrocytes of approxi-
mately 120 days might be shortened due to
inflammation and the fact that hepcidin suppresses ery-
thropoiesis itself, we hypothesized that if hepcidin is
upregulated by inflammation and thereby suppresses
serum iron levels, a measurable effect on Hb level was
expected from seven days onwards after the diagnosis of
sepsis. Furthermore, we anticipated a swift decrease in
inflammation in treated septic patients. For these rea-
sons we determined IL-6 and hepcidin levels for three
days and the rate of Hb decrease within 7 to 14 days.
We were not able to demonstrate a relation of Hb
decrease with a change in MCV, MCH, or RDW. This
does not invalidate the hypothesis that increased hepci-
din attributes to the development of anemia in these
patients. It was previously shown that erythrocyte pro-
genitor cells carry iron transporter ferroportin1B on
their cell membrane [21]. During inflammation systemi-
cally elevated hepcidin down-regulates ferroportin on
these cells, thereby preventing a loss of intracellular iron
and the microcytic anemia that is seen in iron-deficiency
anemia. Therefore, inflammation-associated anemia is
not typically microcytic [22]. Moreover, the observed
effect of hepcidin on the development on anemia may
have been mediated by a direct inhibitory effect on ery-
thropoiesis, rather than by blocking iron transport to
the bone marrow by sequestration.
Interestingly, hepcidin at day one did not predict the
rate of Hb decrease. Probably persistently elevated hep-
cidin levels are necessary to exert a relevant effect on
Hb concentrations. The association we found may be an
underestimation, because the patients in this study were
already anemic at the time of presentation to the emer-
gency ward and likewise it is possible that before pre-
sentation hepcidin levels were even more pronounced.
Nevertheless, although statistically significant, the
observed association between hepcidin and Hb levels is
modest, indicating that other previously mentioned fac-
tors that influence Hb are likely to play a role.
Conclusions
Anemia during acute systemic inflammation evoked by
sepsis is a frequently encountered clinical problem. Up
to now, human data concerning the effect of hepcidin
release on the development of anemia during sepsis
were absent. Our study demonstrates that inflammation
in septic patients is associated with increased hepcidin-
25 concentrations. Moreover, the elevated hepcidin
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concentrations observed in early sepsis negatively corre-
lated with Hb levels during the hospital stay of these
patients. These human in vivo correlations suggest that
hepcidin release is a modulator of anemia in septic
patients with systemic inflammation.
Key messages
• IL-6 concentrations and number of SIRS criteria
present in septic patients are associated with
increased hepcidin-25 concentrations.
• The increase in hepcidin concentrations observed
in early sepsis correlates with the decrease in Hb
levels during their hospital stay and patients with
higher hepcidin concentrations tend to need more
blood transfusions.
• The inflammation-hepcidin release-anemia path-
way is present in patients with sepsis.
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